A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study.
A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study. Ann Oncol. 2017 May 01; 28(5):996-1004.
-
Adjuvants, Immunologic
-
Adjuvants, Immunologic
-
Adult
-
Adult
-
Aged
-
Aged
-
Aged, 80 and over
-
Aged, 80 and over
-
Antineoplastic Combined Chemotherapy Protocols
-
Antineoplastic Combined Chemotherapy Protocols
-
Benzazepines
-
Benzazepines
-
Disease-Free Survival
-
Disease-Free Survival
-
Double-Blind Method
-
Double-Blind Method
-
Doxorubicin
-
Doxorubicin
-
Humans
-
Humans
-
Immunity, Innate
-
Immunity, Innate
-
Kaplan-Meier Estimate
-
Kaplan-Meier Estimate
-
Middle Aged
-
Middle Aged
-
Neoplasm Recurrence, Local
-
Neoplasm Recurrence, Local
-
Neoplasms, Glandular and Epithelial
-
Neoplasms, Glandular and Epithelial
-
Ovarian Neoplasms
-
Ovarian Neoplasms
-
Polyethylene Glycols
-
Polyethylene Glycols
-
Proportional Hazards Models
-
Proportional Hazards Models
-
Treatment Outcome
-
Treatment Outcome